Skip to main content
Premium Trial:

Request an Annual Quote

MorphoSys and GeneFrontier Pen Marketing Collaboration

NEW YORK, Sept. 24 (GenomeWeb News) - MorphoSys of Munich and GeneFrontier of Tokyo will co-market MorphoSys' human antibody technology in Japan, the companies said yesterday.


Under the multi-year agreement, the two companies will market MorphoSys' Human Combinatorial Antibody Library technology in Japanfor both research and therapeutic applications. The deal is part of MorphoSys' effort to expand into new geographic markets.


As part of an ongoing pre-marketing agreement, MorphoSys and GeneFrontier have already conducted several research projects with Japanese partners.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more